Hatchtech, Pty Ltd have announced the completion of their financing round and published new data on the active ingredient in their DeOvo pediculicide product.

TyraTech, Inc, has received notification from the UK regualtory body that their VaMOUSSE!™ head lice product has been registered as a medical device.

The anti-lice product DeOvo, developed by Hatchtech Pty Ltd, has successfully completed its end-of-phase II consultations with the FDA.

Sanofi Pasteur announced this week that Sklice, their ivermectin-based head lice treatment is now commercially available by prescription in the US.

The active ingredient in the DeOvo head lice treatment, produced by Hatchtech Pty Ltd, has been granted a patent by the US Patent and Trademark Office.

Following the recent publication of clinical trial data showing Ivermectin solution to be a safe and effective pediculicide, two further recent items of note:

 A recently-published study has found high occurrance of a genetic mutation in a lice sample which correlates with resistance to permethrin and malathion treatments.

A recently published study has found that ivermectin solution has strong in vivo pediculicide properties.

A petition requesting that lindane be withdrawn from sale as a second-line pediculicide has been denied by the US Food and Drug Administration (FDA).

An assessment and author response to a 2009 clinical trial of spinosad has been published in Archives of Dermatology.